0001638234-16-000003.txt : 20160506 0001638234-16-000003.hdr.sgml : 20160506 20160506145710 ACCESSION NUMBER: 0001638234-16-000003 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160506 DATE AS OF CHANGE: 20160506 EFFECTIVENESS DATE: 20160506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Acer Therapeutics Inc. CENTRAL INDEX KEY: 0001638234 IRS NUMBER: 320426967 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-262700 FILM NUMBER: 161627446 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET, SUITE 2240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-922-3600 MAIL ADDRESS: STREET 1: 222 THIRD STREET, SUITE 2240 CITY: CAMBRIDGE STATE: MA ZIP: 02142 D/A 1 primary_doc.xml X0707 D/A LIVE 0001638234 Acer Therapeutics Inc. 222 THIRD STREET, SUITE 2240 CAMBRIDGE MA MASSACHUSETTS 02142 617-225-7700 DELAWARE None None Corporation true 2013 Christopher Schelling c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Executive Officer Director Promoter Cynthia Lavoie c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director Stephen Aselage c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director John Dunn c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director Luc Marengere c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Director Harry S. Palmin c/o Acer Therapeutics Inc. 222 Third Street, Suite 2240 Cambridge MA MASSACHUSETTS 02142 Promoter Pharmaceuticals Decline to Disclose 06b true 0001638234-16-000002 2016-04-21 false true false 0 8149999 8149999 0 The exact Total Offering Amount and Total Amount Sold are $8,149,999.20 false 6 0 0 740000 true The Issuer expects to use approximately $740,000 of the proceeds for salary and other compensation to the Issuer's executive officers, directors and promoters during the 2016 fiscal year. false Acer Therapeutics Inc. Christopher Schelling Christopher Schelling President & CEO 2016-05-06